NEKTAR THERAPEUTICS (NKTR): Form 8-K filed 2026-11-13
- Accepted by EDGAR
- 2026-11-13 06:02 ET
- Event date
- 2026-11-12
- Accession no.
- 0001213900-26-119146
- Original filing
- SEC EDGAR filing index
AI summary of the filing text. It can contain mistakes; the original filing is authoritative.
Nektar reports $952.9 million cash balance and reiterates cash runway guidance
Nektar Therapeutics reported $952.9 million in cash and investments in marketable securities as of September 30, 2026. Consistent with prior guidance, it expects this balance to extend its cash runway into the third quarter of 2028, past initial data readouts from the Phase 3 ZENITH AD trials in atopic dermatitis in the summer of 2028.
- Cash and investments in marketable securities totaled $952.9 million as of September 30, 2026.
- Nektar expects its cash runway to extend into the third quarter of 2028, consistent with prior guidance.
- Initial data readouts from the Phase 3 ZENITH AD trials in atopic dermatitis are expected in the summer of 2028.
earningsguidance
Items reported
- Item 7.01: Regulation FD Disclosure
The company is making information public under Regulation FD, which requires broad public disclosure of material information shared with certain market participants. Investor presentations and press releases are common. Like Item 2.02, this information is generally "furnished" rather than "filed".
Documents
| Type | Description | Document |
|---|---|---|
| 8-K | CURRENT REPORT | ea0312139-8k_nektar.htm |
The summary above was generated by AI from the filing text and checked automatically against it. Read the original documents on SEC EDGAR. How to read an 8-K.